This scheme aims to harness biological and mechanistic insights to provide new targets and approaches for cancer prevention.The Biology to Prevention Awards aim to stimulate translational research that will build and use greater biological and mechanistic understanding of cancer aetiology, genesis and risk, in order to lead to precision prevention interventions. We expect applicants to clearly justify the line of sight from the proposed work to eventual impact on lowering cancer risk or incidence (as outlined in our Prevention Research Strategy). It is important that this line of sight has been fully considered.

These awards are for researchers at all career stages across any research area, including those from non-traditional cancer prevention fields (such as other non-communicable disease areas with potential common upstream causal risk factors, or those working in the context of therapeutic target identification and innovation) to engage with cancer prevention research. They support development of new collaborative partnerships, and truly interdisciplinary, innovative approaches. Collaborations between existing cancer prevention researchers (including population and behavioural scientists) and biologists, geneticists, immunologists, drug developers or other new entrants to cancer prevention research are strongly encouraged.

Areas that could be considered include but are not limited to:
– building on biological insight into mechanisms of early pre/cancerous changes to validate potential new prevention targets
– translational research to develop and establish proof of principle for novel preventive approaches (pharmacological, dietary, behavioural or immunological)
– development of novel approaches to treating/eliminating/modulating pre-cancerous lesions or changes
– use of mechanistic insight or risk stratification to better target existing preventive approaches (pharmacological, dietary, behavioural or immunological)
– developing and implementing precise understanding of the biological mechanisms mediating cancer risk from modifiable risk factors to reduce that risk (especially those that exacerbate health inequities)
– gaining a mechanistic understanding of how, and in whom, repurposed drugs/dietary compounds confer their cancer preventive properties, and/or how these could subsequently be used for precision preventive approaches
– identification and validation of biomarkers/surrogate endpoints which might predict future cancer emergence or the preventive effect of interventions
– novel approaches to prevention research using surrogate endpoints and innovative trial designs